1096 related articles for article (PubMed ID: 25616671)
21. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
23. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
24. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
Bagust A; Greenhalgh J; Boland A; Fleeman N; McLeod C; Dickson R; Dundar Y; Proudlove C; Shaw R
Pharmacoeconomics; 2010; 28(6):439-48. PubMed ID: 20465313
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Auvray M; Tougeron D; Auclin E; Moulin V; Artru P; Hautefeuille V; Hammel P; Lecomte T; Locher C; Sickersen G; Coriat R; Lecaille C; Vernerey D; Taieb J; Pernot S
Clin Colorectal Cancer; 2020 Mar; 19(1):39-47.e5. PubMed ID: 31648924
[TBL] [Abstract][Full Text] [Related]
27. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
28. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
29. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
31. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
32. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
33. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
34. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
36. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
37. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
38. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
39. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
André T; Chibaudel B
Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]